Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens-Reference-Cited by-同舟云学术

Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

Published:2024-02-17 Issue:4 Volume:38 Page:918-922
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Sébert Marie^ORCID,Freiman Lucie^ORCID,Chaffaut Cendrine,Guerci Agnès,Peterlin Pierre,Thépot Sylvain,Beyne-Rauzy Odile,Park Sophie,Cluzeau Thomas^ORCID,Chermat Fatiha,Fenaux Pierre,Preudhomme Claude,Clappier Emmanuelle,Chevret Sylvie,Adès Lionel^ORCID,Duployez Nicolas^ORCID,Duchmann Matthieu^ORCID

Funder

Fondation Bettencourt Schueller

Groupe Français des Myélodysplasies

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02180-3.pdf

Reference15 articles.

1. Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:1–14.

2. Aguirre LE, Al Ali N, Sallman DA, Ball S, Jain AG, Chan O, et al. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023;37:1530–9.

3. Baer C, Huber S, Hutter S, Meggendorfer M, Nadarajah N, Walter W, et al. Risk prediction in MDS: independent validation of the IPSS-M-ready for routine? Leukemia. 2023;37:938–41.

4. Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao L-P, et al. Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes. J Clin Oncol J Am Soc Clin Oncol. 2023;41:2827–42.

5. Huber S, Haferlach T, Müller H, Meggendorfer M, Hutter S, Hoermann G, et al. MDS subclassification—do we still have to count blasts? Leukemia. 2023;37:942–5.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring molecular changes in the management of myelodysplastic syndromes;British Journal of Haematology;2024-06-27